2019-2020 BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Jeanine M. D’Armiento, MD, PhD
Chair

Jennifer Jopp
Secretary

Elizabeth Johnson
Vice Chair

Gordon Cadwgan, PhD
Past Chair

Fred Walsh
Treasurer

Martin R. Zamora, MD
Physician Director

BOARD MEMBERS

Virginia Clark, MD

Kenneth Irvine

Peg Iverson

Ann Knebel
PhD, RN

Noel G. McElvaney, MD

James K. Stoller, MD, MS

Frank Willersinn, MD
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

Alphas and everyone affected by this genetic condition are at the core of our mission, and every time we are faced with a challenging decision, we ask ourselves two basic, yet powerful questions:

- Does this bring us closer to a cure for Alpha-1?
- Does it benefit the Alpha-1 community?

Inclusive and innovative have always been key words for the Alpha-1 Foundation since our inception under the leadership of John W. Walsh. The Foundation is constantly on the move to strengthen our community, support cutting edge science, and reach our goal and core of our mission: to find a cure for Alpha-1.

The Foundation’s connection between patients, caregivers, scientific and medical professionals, industry and government, is the axis of our successful transition into the future. We always strive to identify improved ways to serve those affected by Alpha-1 and enhance our research portfolio.
2020 marked the 25th anniversary of the Alpha-1 Foundation. We continued to celebrate our rich history of research success, our latest research progress, highlight some of our outstanding researchers and recognize the successes of our Alpha-1 community over the past year.

The accomplishments of our organization reflect our commitment to the success of our investigators and the deployment of new knowledge, therapies, and insights that improve the lives of Alpha-1 patients nationally and globally. The programs of the Foundation drive its mission to find a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and improve the lives of people affected by Alpha-1 worldwide. We are grateful for the outstanding commitment of medical and scientific leadership, volunteers, fundraisers, and donors and for their dedication to the Alpha-1 patient community over the past 25 years.

In this fiscal year, the last quarter was heavily virtual due to the COVID-19 pandemic. The Foundation assembled a COVID-19 Medical Leadership Team to provide expert advice specific to Alphas during this time. The new virtual environment challenged the Foundation to be creative and proactive in the ways we educate and communicate with the community at large. We learned to pivot and focus on how to provide access to education and information for our highly vulnerable community.
The Alpha-1 Foundation prides itself on being the leader in information for newly diagnosed Alphas and their families. We strive to have the most up-to-date information in physician’s offices around the country for patients to access. The Alpha-1 Foundation website (www.alpha1.org) is most often the first contact that newly diagnosed Alphas and their family members have with the Alpha-1 Foundation and, in many cases, their first source of information about Alpha-1 Antitrypsin Deficiency (Alpha-1). The Foundation launched a new and enhanced website that provides a searchable, user-friendly platform for all audiences that is easily updated to provide the latest information to the community and general public.

The Alpha-1 Foundation uses its social media platforms to connect with constituents, raise awareness and provide information on upcoming events, important information, timely topics and Foundation programs. With the engagement of our followers on the three active platforms (Facebook, Instagram and Twitter), we are able to effectively spread the word about fundraising campaigns, new initiatives, advocacy, community education events and scientific meetings and conferences. The social media channels have allowed an increase in awareness for Alpha-1 Antitrypsin Deficiency and the Alpha-1 Foundation’s brand while connecting with followers in real-time. Statistics have showed that the simpler the message, the higher response, thus the Foundation incorporates posts with basic information on Alpha-1 on a scheduled basis.
The Alpha-1 Foundation’s monthly Community Currents e-newsletter keeps the Alpha-1 community and volunteer leadership up to date on Alpha-1 related news, upcoming events, research, programs, fundraising activities, and the Alpha-1 Research Registry. The wide distribution of this newsletter to all active constituents allows us to inform our readers on how they can continue to contribute to the Alpha-1 Foundation’s mission by consistently highlighting current initiatives.

A designated COVID-19 page was created on the website for COVID-19 providing educational and informative guidance and recommendations for Alphas. The easy to access page provided resources that were continuously updated with access to pertinent issues that Alphas were facing including access to home infusions, marketplace coverage and vaccine access.

Twenty-two webinars were hosted on topics related to the COVID-19 pandemic in order to keep patients and their families informed during this uncertain time. The top three presentations of the year included: A View from the front lines of COVID-19, Other Diseases that are concurrent with Alpha-1, and Mental Health During COVID-19 Webinar.

The Alpha-1 Foundation provided a series of webinars for the Alpha-1 Families Virtual Support Group that specifically targets parents with information relevant to their needs. The two webinars centered around COVID-19 and the risks to Alpha-1 children as well as a webinar on Alpha-1 children returning to school. The Foundation is also exploring the best way to reach and serve the young adult community, as well as opportunities to engage this group in leadership and community opportunities.
ALPHA-1 OUTREACH & EDUCATION

Nine episodes of the Alpha-1-to-One Podcast were recorded and shared to expand the Foundation’s existing media platform to an audio medium that interests existing readers of the ALPHA-1-To-One magazine, but most importantly, reached a different audience that is searching for information about Alpha-1. The Podcast continues to build on the success of the magazine and its brand equity within the community. Like the magazine, it provides “Practical advice, personal experiences and pertinent news for people touched by Alpha-1,” with strong appeal to the next generation of the Alpha-1 community. We took the opportunity to modify our podcast format during the pandemic to address immediate concerns of Alphas around the world. Hosted by Alpha, Richard Lovrich, the Foundation worked closely to examine topics and questions that were coming in through the information line and social media. The following podcasts were created in response.

The Alpha-1 Foundation circulated three issues of the Alpha-1-to-One Magazine this year. The Fall issue of the magazine, “The Cure Depends on You,” focused on the new Alpha-1 Research Registry and the patient’s integral role in the cure. The Winter Issue, “Knowledge is Power,” focused on Family Testing, and the Spring Issue, “25 Years,” focused on the Foundation’s outstanding commitment to the Alpha-1 patient and research over more than two decades.

ALPHA-1 AWARENESS

Alpha-1 Awareness Month creates awareness of Alpha-1 leading up to and during the month of November. The Foundation equips the Alpha-1 community with the necessary resources to participate, regardless of their prior level of involvement in the community. During the month of November, a dedicated web page, online training, digital resources, media outreach, community events, and a social media calendar are available specifically for awareness. The 2019 Alpha-1 Virtual Walks allowed anyone who wanted to make a difference in the Alpha-1 community to contribute in their own style, in their own time, and at their own pace.
The Alpha-1 Foundation public policy program enhances the delivery of the organization’s mission by striving to improve the lives of individuals living with Alpha-1 and promote research for a cure. The agenda is focused on Alpha-1 research, advocating for the community, promoting access to care and support at the state and federal level. The Foundation addresses the challenges ranging from diagnosis, treatment, research, cost of care, access to specialists, reimbursement, and access to therapy. An important component of our work includes fostering and maintaining ongoing relationships and memberships with partner organizations and key coalition groups that amplify the voice of the Foundation by channeling communications to members of Congress and their staff, as well as federal agencies in both the regulatory and scientific development areas.

**ALPHA-1 ADVOCATES AND THE FOUNDATION REPRESENTED ALPHA-1 AT:**

- 2020 Rare Disease Day
- Rally for medical research day
- PPTA Annual Fly-in
- Many forums convened for not-for-profit organizations and patients
Alpha-1 patients worldwide face many challenges including little to no awareness of their condition, long delays in getting the correct diagnosis, inadequate clinical care by physicians unfamiliar with the standard of care for lung and liver disease caused by Alpha-1, and, in many cases, limited or no access to augmentation therapy. In the virtual world, global patients are able to access and participate in all of the Foundation’s e-learning and comprised about 20% of the Virtual Alpha-1 National Conference registrants in 2020.

Close relationships across international patient, clinician, and scientific communities is aimed to increase awareness, encourage earlier diagnosis and family testing, promote disease management, and enhance participation in patient registries. Alpha-1 Global develops avenues in which the global community can collaborate. The Alpha-1 Foundation has enhanced these close relationships by restructuring Alpha-1 Global’s outreach and providing further mentorship and leadership to smaller patient organizations and country leaders.

In February 2020, Alpha-1 Global announced that three Alpha-1 organizations were selected to be the inaugural pilot Alpha-1 Global Hub Centers: Alpha-1 Foundation Ireland, Alpha-1 Association of Australia, and Fundación Argentina de Alfa-1. In selecting these organizations, Alpha-1 Global established a Hub Center on three different continents for the purpose of serving the regional Alpha-1 communities by attempting to establish a peer-to-peer network of organizations supporting other organizations with similar goals.
ALPHA-1 COMMUNITY

The Building Friends for a Cure (BFC) program is a critical component of the Foundation’s goal to raise awareness of Alpha-1 while providing tools for the community to raise funds to support research and related programs. These events promote community interaction between Alphas, their friends and family, investigators, industry, and medical professionals, including Clinical Resource Center (CRC) physicians and staff. This year, many events marked the 25th Anniversary of the Alpha-1 Foundation. The community leveraged the occasion to garner more awareness, support, and participation at events throughout the country.

Alpha-1 Community Events:

- Duck Race 2019 hosted by Larry and Marian Hoffman.
- Step Forward for Colorado 2019
  - Dr. Sandhaus hosted his 29th annual picnic in Colorado in conjunction with the local Education Day.
- Escape to the Cape 2019
  - This event gave us the opportunity to continue our long-standing partnership with The American Lung Association of New England. The event continues to grow with 100 riders and 80 volunteers helping raise over $255,000.
- Tampa Dinner Dance 2019 hosted by Alpha-1 patient.
- Virtual Walk 2019 & November 2019 Alpha-1 Awareness Month
  - For 30 days, in 34 states, friends and family supported one strong mission to find a cure. The community set up 72 teams to total 970 walkers who walked, ran, or found their unique way to raise awareness and over $86,000 community dollars. In November, a total of 91 Facebook posts reached over 165,000 pairs of eyes and generated over 12,000 actions. Tweets saw a total of 47,000 views, and Instagram reached over 5,000 people and generated over 51,000 views, overall.
• Celtic Connection 2020
  - Celtic Connection is the largest gathering of Alpha-1 friends and family (outside of the Alpha-1 National Conference) who come together for a St. Patrick’s Day gala. The committee, comprised of local Alphas and friends, worked diligently during the winter months to make the evening a huge success. The event took place just before the worldwide pandemic was announced and COVID-19 would forever change our lives. The highlight of this event is the passing on of the famous “shillelagh award,” which was awarded to Dr. Ginger Clark from the University of Florida.

- Annual Walk in Memory of Jim Quill.
- “Yoga for Better Breathing Series” with Alpha and Certified Instructor, Chris Riely.
- Yard Marathon by Kristen Sheppard.

VIRTUAL WALK
JOIN THE QUILL FAMILY TO REMEMBER JIM’S LEGACY ON APRIL 25TH FOR A VIRTUAL WALK
After 7 months on the trail, Jonathan Maidment finished his thru-hike of the Pacific Crest Trail in October 2019. He was able to raise $102,614 in community dollars. Included in the outreach for the event was a social media challenge that engaged followers to like and share a remarkable photo of Maidment. The community was challenged to 2,650 likes, representing the 2,650 miles of the trail, and a generous $20,000 donation was made to Maidment’s fundraising goal by AlphaNet. The post has been liked, commented on, and shared over 4,000 times.

In January 2020, Jonathan Maidment announced that he will return to the trails again. He would be hiking the Continental Divide Trail, which consists of 3,100 miles between Mexico and Canada through the United States, along the Rocky Mountains, and crossing Montana, Idaho, Wyoming, Colorado, and New Mexico. The Triple Crown of Hiking refers to the three major U.S. long-distance hiking trails: the Appalachian Trail (AT), the Pacific Crest Trail (PCT), and the Continental Divide Trail (CDT). The Triple Crown is not an easy feat, as hikers must complete a total of nearly 8,000 miles across 22 states with one million feet of cumulative elevation gain. It is estimated that only about 600 people have hiked the Triple Crown.
The Alpha-1 Education Day Series changed drastically during the 2020 calendar year due to the COVID-19 pandemic. Shortly after the first Alpha-1 Education Day in February held in Los Angeles, California, the country relied heavily on healthcare workers across the United States to care for those affected by COVID-19 and many of our experts were called to respond to the increased need for medical attention in their regions. Our appreciation and respect go out to each and every one of them for the sacrifices they have made.

The health and safety of the Alpha-1 community are a top priority at the Alpha-1 Foundation. With that in mind and out of an overabundance of caution, the Alpha-1 Foundation postponed several Alpha-1 Education Days and later moved them to a virtual platform.

The Fiscal Year 2020 Alpha-1 Education Days had over 500 people in attendance over four (4) events:

- Denver – August 3, 2019
- Minneapolis – September 21, 2019
- Philadelphia – October 26, 2019
- Los Angeles – February 29, 2020
Due to the COVID-19 pandemic, the 2020 Alpha-1 National Conference was converted to a 3-day virtual event. The event had nearly 2,000 people attend online. Of those who attended, 93%

were Alphas and family members. Alpha-1 Foundation Board members, Support Group Leaders, and Foundation staff took an active role at the conference by engaging in chats with attendees. The theme of the conference was the 25th Anniversary of the Alpha-1 Foundation. Research is the center of the Foundation’s mission, finding a cure for Alpha-1 is the number one priority and the conference focused on research-past, present, and future.

2020 highlights included four exciting and inspirational keynotes provided by industry sponsors, over eighteen expert presentations, and six live Q&A sessions. Prominent specialists, medical doctors, Alpha-1 experts, scientists, researchers, and industry. Leaders in Alpha-1 explained the latest medical findings, therapeutic developments, and research outcomes during the three-day event. The virtual event included scientific sessions to provide patients with the opportunity to hear about the latest updates towards a cure.

On the virtual platform during the conference, there were over 40,000 visits and impressions, including visits to the Exhibit Hall, videos and presentations watched, engaged one-on-one chats, and content downloads.
The Alpha-1 Research Registry was established in 1997 by the Alpha-1 Foundation to establish a research resource that would promote the development of improved treatments and ultimately a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1). The Alpha-1 Research Registry is a confidential database of diagnosed Alphas and carriers willing and able to participate in research studies and clinical trials for new therapies. In 2019, the Foundation began the process of bringing the Alpha-1 Research Registry in-house. This decision was based on recommendations made by the NIH that nonprofit organizations should manage their own registries.

Under the direction of the Registry’s Principal Investigator, Dr. Jeanine D’Armiento, the Alpha-1 Research Registry is located at the Alpha-1 Foundation office in Coral Gables, FL. The Registry is approved and overseen by the New England Institutional Review Board. The Registry is also guided by the Alpha-1 Foundation’s Board of Directors and an advisory committee comprised of leaders in the medical, patient, scientific, and ethics from the Alpha-1 community. Each staff member who interacts with the Registry has received good clinical practices certification.

The Alpha-1 Research Registry online portal officially launched in February 2020 at the Los Angeles Alpha-1 Education Day. The online portal has been created to make enrollment as easy as possible so that individuals complete registration, sign an informed consent, complete the patient questionnaire, and upload medical tests and labs online. REDCap is accessed via encrypted and certified laptops and/or desktops. Individuals may continue to request hard copies of the informed consent and questionnaire be mailed to them.
FAMILY TESTING

The Foundation redesigned its Alpha-1 Coded Testing (ACT) program. The program is now entirely housed at the University of Florida, under the direction of Dr. Mark Brantly. The It’s All in the Family brochure is included in the ACT Study results mailed to those who have a rare allele. The University of Florida also provides genetic counseling services for the Foundation so there has been a streamlined and cohesive approach to individual testing, family testing, and providing genetic counseling services. It is expected that this streamlined approach will play a major role in the detection of family members.

The ACT Study has enrolled over 45,000 individuals since 2001 collecting data on the impact of at-home genetic testing. This year, severely deficient test results have returned at 4.8% and one deficient allele at 56% of tested individuals. The number of individuals screened through the ACT Study grows each year. Increased testing is a result of the Foundation’s Alpha-1 awareness and education efforts with patients and physicians. Due to the volume of requests, the Foundation estimates that it will see a 20% increase in FY 2021.
The Alpha-1 Foundation is proud and grateful for the opportunity to have collaborated with the FDA, Center for Biologics Evaluation and Research (CBER), and the National Institutes of Health (NIH) in organizing the public workshop entitled “Developing Alpha-1 Antitrypsin Therapeutics,” on Monday, September 16, 2019, in Bethesda, Maryland. The agenda was designed to review current science and questions about clinical trial design for next-generation plasma therapies and new novel therapies for Alpha-1 Antitrypsin Deficiency (Alpha-1). The FDA made a commitment to draft guidelines based on the agreements reached during the public workshop. Unfortunately, CBER has been focused almost exclusively on the development of new vaccines for COVID-19 during the current pandemic. This makes it even more important that the Foundation work to publish a paper with the recommendations of the day that we captured by our scientific writer.
The Foundation continues its efforts in organizing, promoting, and convening highly successful and impactful scientific meetings and conferences on Alpha-1. The Foundation’s first scientific meeting of 2020, the 19th Gordon L. Snider Critical Issues Workshop, was convened on March 2-3, 2020 in Bethesda, Maryland. The workshop, entitled “Biomarkers and Endpoints for Drug Development in Alpha-1 Antitrypsin Deficiency” featured five expert-led sessions in the following areas: Biomarkers for AATD Lung & Liver Disease, Newer Blood Based Biomarkers, Imaging as Biomarkers, and Clinical Biomarkers. The purpose of the meeting was to evaluate current knowledge and inform areas of research that will fill in the knowledge gaps and influence the FDA moving forward. The workshop was well attended with over 85 attendees, including representatives from academia, NIH, FDA, industry voluntary health care organizations and patients. The Foundation would like to thank the workshop’s co-chairs, Dr. Gerry McElvaney and Dr. Virginia Clark, for their input into the conference program and for inviting and securing the participation of an international group of experts to present data and partake in the ensuing discussions.
RESEARCH GRANT AWARDS

Philip Bird, Ph.D.
Monash University, Australia

“Use of transgenic zebrafish to identify modulators of Z-antitrypsin induced pathology”

Adam Gerber, M.D., Ph.D.
Trustees of Columbia University

“Direct effect of mutant alpha-1 antitrypsin on the lung”

Monica Goldklang, M.D.
Trustees of Columbia University

“In vivo functional imaging in alpha-1 antitrypsin deficiency”

Bibek Gooptu, M.D., Ph.D.
University of Leicester, UK

“Structural studies of immunomodulation in alpha-1 antitrypsin”

Craig P. Hersh, M.D.
Brigham and Women’s Hospital

“Is COPD in Alpha-1 Antitrypsin MZ carriers the same as COPD in non-carriers?”

Maurizio Molinari, Ph.D.
Fondazione per l’Istituto di Ricerca Biomedicina Bellinzona, Switzerland

“The role of ER-to-lysosome-associated degradation in clearance of polymerogenic ATZ”
Nunzia Pastore, Ph.D.
Telethon Institute of Genetics and Medicine, Italy

“Investigating the effects of mutant a1-antitrypsin on liver cell fate and HCC development”

Keith Robertson, Ph.D.
Mayo Clinic

“Discovery and validation of non-invasive epigenetic biomarkers for AATD liver disease”

Richard Sifers, Ph.D.
Baylor College of Medicine

“Investigation of infantile end-stage liver disease factors”

Nazli Khodayari, Ph.D.
University of Florida

“Novel biomarkers for alpha 1-antitrypsin mediated liver disease in circulating exosomes”

Andrew Wilson, M.D.
Trustees of Boston University, B U Medical Campus

“Alpha-1 Foundation CRC Registry Data Transfer”
## STATEMENT OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$2,884,656</td>
<td>$1,878,690</td>
</tr>
<tr>
<td>Investment securities</td>
<td>$14,745,676</td>
<td>$17,733,069</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>$2,079,860</td>
<td>$1,689,367</td>
</tr>
<tr>
<td>Due from TAP</td>
<td>-</td>
<td>$2,231</td>
</tr>
<tr>
<td>Other current assets</td>
<td>$35,014</td>
<td>$30,884</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>$19,745,206</td>
<td>$21,334,241</td>
</tr>
<tr>
<td>Investment securities - non-current</td>
<td>$7,277,341</td>
<td>$4,146,938</td>
</tr>
<tr>
<td>Investment in TAP</td>
<td>$25,312</td>
<td>$94,753</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>$24,345</td>
<td>$43,179</td>
</tr>
<tr>
<td>Other assets</td>
<td>$25,134</td>
<td>$47,737</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$27,046,714</td>
<td>$25,477,342</td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable/accrued expenses</td>
<td>$1,889,143</td>
<td>$2,457,126</td>
</tr>
<tr>
<td>Due to TAP</td>
<td>-</td>
<td>$10,124</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$84,000</td>
<td>$84,000</td>
</tr>
<tr>
<td>Refundable advances</td>
<td>$200,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>$2,173,143</td>
<td>$2,551,250</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without donor restrictions</td>
<td>$22,278,931</td>
<td>$20,465,616</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>$2,594,640</td>
<td>$2,460,476</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>$24,873,571</td>
<td>$22,926,092</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$27,046,714</td>
<td>$25,477,342</td>
</tr>
</tbody>
</table>
# Statement of Activities and Changes in Net Assets

<table>
<thead>
<tr>
<th>Changes in net assets without donor restrictions</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions, bequests and grant revenues</td>
<td>$5,651,004</td>
<td>$6,425,297</td>
</tr>
<tr>
<td>Donated shares</td>
<td>$32,116</td>
<td>$104</td>
</tr>
<tr>
<td>Fund raising revenues</td>
<td>$150</td>
<td>$1,689,367</td>
</tr>
<tr>
<td>Net realized and unrealized investment gains</td>
<td>$1,216,148</td>
<td>$2,195,576</td>
</tr>
<tr>
<td>Other income</td>
<td>$821,094</td>
<td>$75,4091</td>
</tr>
<tr>
<td>Net assets released from restriction - satisfaction of program restrictions</td>
<td>$2,119,272</td>
<td>$2,615,807</td>
</tr>
<tr>
<td>Total support/revenue without donor restrictions</td>
<td>$9,839,784</td>
<td>$12,266,930</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses without donor restrictions</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and Clinical Studies</td>
<td>$4,652,750</td>
<td>$5,396,481</td>
</tr>
<tr>
<td>Patient Education</td>
<td>$1,075,038</td>
<td>$1,832,268</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>$300,401</td>
<td>$589,784</td>
</tr>
<tr>
<td>Total program services</td>
<td>$6,028,189</td>
<td>$7,818,533</td>
</tr>
<tr>
<td>Administrative and general</td>
<td>$750,737</td>
<td>$723,945</td>
</tr>
<tr>
<td>Fund raising</td>
<td>$631,984</td>
<td>$861,739</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>$1,382,721</td>
<td>$1,585,684</td>
</tr>
<tr>
<td>Total expenses without donor restrictions</td>
<td>$7,410,910</td>
<td>$9,404,217</td>
</tr>
<tr>
<td>Change attributed to loss from TAP</td>
<td>$615,559</td>
<td>$1,009,604</td>
</tr>
<tr>
<td>Increase in net assets without donor restrictions</td>
<td>$1,813,315</td>
<td>$1,853,109</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Changes in net assets with donor restrictions</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions, bequests and grant revenues</td>
<td>$2,253,436</td>
<td>$2,308,340</td>
</tr>
<tr>
<td>Net assets released from restriction</td>
<td>$2,119,272</td>
<td>$2,615,807</td>
</tr>
<tr>
<td>Changes in net assets with donor restrictions</td>
<td>$134,164</td>
<td>$307,467</td>
</tr>
<tr>
<td>Increase in net assets</td>
<td>$1,947,479</td>
<td>$1,545,642</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>$22,926,092</td>
<td>$21,380,450</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$24,873,571</td>
<td>$22,926,092</td>
</tr>
</tbody>
</table>
FINANCIAL POSITION GRAPHS

Alpha-1 Foundation
Functional Expenses
For The Fiscal Year Ended June 30, 2020

Research and Clinical Studies, $4,652,750, 63%

Research and Clinical Studies, $4,652,750, 63%

Patient Education, $1,075,038, 14%

Patient Advocacy, $300,401, 4%

Administration and general, $750,737, 10%

Fund raising, $631,984, 9%

Alpha-1 Foundation
Gross Revenues By Classification
For the Fiscal Year Ended June 30, 2020

Unrestricted Contributions, $2,833,270, 28%

Other Income, $2,037,242, 20%

AlphaNet, $2,850,000, 29%

Restricted Contributions, $2,253,438, 23%
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and improving the lives of people affected by Alpha-1 worldwide. The Alpha-1 Foundation has invested more than $81 million to support Alpha-1 research and programs at more than 119 institutions in North America, Europe, the Middle East and Australia.

The Alpha-1 Research Registry is a confidential database of people with Alpha-1 (Alphas) and Alpha-1 carriers. It is a resource for investigators seeking Alphas to participate in clinical trials, surveys, and other scientific and medical activities. For more information, email alpha1registry@alpha1.org or call toll-free 1-877-228-7321 ext. 252. https://www.alpha1.org/alphas-friends-family/resources/participate-in-research/

Alpha-1 Coded Testing provides free, confidential testing administered through a research study that evaluates perceived risks and benefits of genetic testing. For more information, email alphallab@alphaone.ufl.edu call toll free 1-855-476-1227 https://www.alpha1.org/healthcare-providers/testing-and-treatment/alpha-1-coded-testing-study/.

The Support Network is comprised of over 80 support groups nationwide that provide guidance and education to Alphas and family members, create awareness in local communities, and advocate for national and state issues that affect Alphas. Four Virtual Support Groups provide a forum for topics such as Alpha-1 Kids, Pre & Post Transplant issues, Caregivers and Timely Topics. To find a support group near you, visit a1f.org/support-groups.

The Patient Information Line 1-800-245-6809 is available free of charge to anyone affected by Alpha-1 and provides support and answers to topics such as Alpha-1 testing, emotional impact, and physician and support group referrals.

The Genetic Counseling Program 1-855-476-1227, based at the University of Florida, is a free and confidential service that provides direct contact to a genetic counseling service to provide information on the risks and benefits of testing for Alpha-1, interpreting test results, understanding the genetics of Alpha-1, and other issues associated with having a genetic illness. https://www.alpha1.org/alphas-friends-family/support/genetic-counseling/

The Peer Guide Program 1-877-346-3212 connects newly diagnosed Alphas with other Alphas who have a similar set of circumstances to provide emotional support, discuss resources available and assist in making choices about health.
The Oxygen Fund provides oxygen equipment for Alphas in financial need to travel to physicians, hospitals, Alpha-1 educational events and other activities. For more information contact jcollins@alpha1.org or call 1-877-228-7321 ext. 251. https://www.alpha1.org/alphas-friends-family/resources/oxygen-resources/

Patient Education Programs include an annual National Education Conference which brings together over 600 Alphas, caregivers, industry representatives, clinicians, allied health care workers and scientists to discuss a wide range of Alpha-1 related topics. For more information, visit alf.org/alpah1conference. Additionally, a series of Alpha-1 Education Days are held each year in various cities throughout the U.S. to bring patient education to a regional audience. For more information, visit alf.org/educationdays. Recordings of these events are available via E-Education at alf.org/education-videos.

Building Friends for a Cure is a program designed to nurture ongoing friendships in the Alpha-1 community. The goal is to increase awareness and raise funds for research and related programs which will ultimately lead to a cure for Alpha-1. By becoming involved in fundraising efforts, such as virtual events, letter writing campaigns, and other social and sporting events, you are making a difference. Visit alf.org/building-friends, contact amcbride@alpha1.org or call 1-877-228-7321 ext. 233 for more information.

The Alpha-1 Kids Program is geared to the special needs and concerns of parents of children with Alpha-1. A committee of volunteer parents helps direct the program, which consists of a hotline, age appropriate informational books, a virtual support group and a parent peer guide program. For more information, visit alf.org/alpah1-kids or contact chenderson@alpha1.org.

Educational resources about Alpha-1 and related topics are available for Alphas, their families, caregivers and healthcare providers. Informational brochures such as ‘What is Alpha-1?’, ‘Am I an Alpha Carrier?’, ‘The Liver and Alpha-1’, ‘It’s All In The Family: Family Testing’ are available to download and order through our website, alf.org/al1-publications, or by calling toll-free 1-877-228-7321 ext. 251. The Alpha-1 to One Magazine is published three times a year and includes timely articles about Alpha-1 research and Alpha life, as well as answers from Alpha-1 experts to questions from the Alpha-1 Community. Join the mailing list here alf.org/alphas-friends-family/resources/join-mailing-list/ to receive the magazine. Presentations from previous Alpha-1 educational events are available via E-Education at alf.org/education-videos.
The Foundation’s Public Policy Program advocates for the Alpha-1 community by monitoring and influencing legislative and regulatory issues. Primary concerns include stimulating medical research, blood product safety, developing new therapies, screening and detection, access to care and reimbursement, federal and state funding, education, awareness and the recognition of the special needs of people with Alpha-1. For more information, visit a1f.org/action-alert.

Grants and Awards: The Foundation’s peer-reviewed grants program is intended to promote research that will lead to improved health for Alphas and ultimately, find a cure. We offer grants for both basic science and clinical research. For more information, contact David Fernandez at dfernandez@alpha1.org or call 1-877-228-7321 ext. 242.

The Alpha-1 Foundation DNA & Tissue Bank at the University of Florida is the central storage site for DNA and tissue samples from Alphas and other donors. The Bank is a resource for researchers investigating Alpha-1 and other conditions. Researchers should contact David Fernandez at dfernandez@alpha1.org or call 1-877-228-7321 ext. 242. For other information, call toll-free 1-866-284-2708.

The Targeted Detection Program promotes worldwide awareness among medical professionals, the media and public and the identification of Alphas in population groups at risk. For further information, please call 1-877-228-7321 ext. 306.

The Alpha-1 Clinical Resource Center Network is a steadily growing group of centers throughout North America that specialize in patient care and education for those with Alpha-1. Centers also offer other resources for Alphas such as support groups, transplant centers and pulmonary rehabilitation. Alphas and their physicians are encouraged to contact their regional Clinical Resource Center for information and guidance. To find an Alpha-1 specialist near you, visit a1f.org/alpha1doc. For more information, contact David Fernandez at dfernandez@alpha1.org or call 1-877-228-7321 ext. 242.

Scientific Meetings, Conferences, Workshops, Working Groups and Symposia bring scientists together to focus on special topics related to Alpha-1, to advance knowledge of the genetic condition and to work toward new therapies and a cure. For more information, contact Adriana De Arce at adearce@alpha1.org or call 1-877-228-7321 ext. 269.
The Alpha-1 Global Initiative works on a global, national and local level to enhance care and support for all those affected by Alpha-1. The Foundation is committed to providing reliable resources and information worldwide. As part of the Global Alpha-1 Initiative, the Foundation is creating new tools focusing on connecting Alphas all over the world with resources – and with each other. For more information, visit alpha-1global.org, contact Randel Plant at rplant@alpha1.org or call 1-877-228-7321 ext. 306.

Access and Reimbursement: The Alpha-1 Foundation is committed to providing the tools and resources necessary to assist Alphas in making informed decisions about their healthcare plan and assistance program selection. Patients with questions or issues concerning access or reimbursement should contact Cathey Henderson at 1-800-245-6809 or chenderson@alpha1.org. https://www.alpha1.org/alphas-friends-family/resources/assistance-organizations/

The Clinical Trial Outreach and Education Program is an online tool used to educate Alphas about clinical trials with curated educational materials towards Alpha-1. For more information, visit https://www.alpha1.org/alphas-friends-family/resources/clinical-trials/ or contact Philip Chieng at pchieng@alpha1.org or call 1-877-228-7321 est. 206.
The Alpha-1 Foundation’s Honor Gallery salutes the individuals, corporations and foundations that share our commitment to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. The Foundation gratefully welcomes a number of new members who have supported our mission for the first time through their generous contributions.

The Foundation acknowledges the continued support of the many long-time donors who have invested in our mission through contributions, events and workplace giving. It is with sincere gratitude and appreciation that we recognize our Honor Gallery. The following is a list of donors who contributed $500 or more between July 1, 2019 and June 30, 2020.

<table>
<thead>
<tr>
<th>Category</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.5 Million or More</td>
<td>AlphaNet, Inc.</td>
</tr>
<tr>
<td></td>
<td>$1 Million - $2,499,999</td>
</tr>
<tr>
<td></td>
<td>CSL Behring, L.L.C.</td>
</tr>
<tr>
<td></td>
<td>Grifols</td>
</tr>
<tr>
<td></td>
<td>$500,000 - $999,999</td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceutical Company</td>
</tr>
<tr>
<td></td>
<td>Vertex Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>$10,000 - $24,999</td>
<td>Arrowhead Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Anonymous Donor</td>
</tr>
<tr>
<td></td>
<td>Apic Bio, Inc.</td>
</tr>
<tr>
<td></td>
<td>Beam Therapeutics, Inc.</td>
</tr>
<tr>
<td></td>
<td>Dicerna Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Rachel L. and Jon E. Hagstrom</td>
</tr>
<tr>
<td></td>
<td>Kamada, Ltd.</td>
</tr>
<tr>
<td></td>
<td>Carol and Thomas G. Lavell</td>
</tr>
<tr>
<td></td>
<td>Presidio Networked Solutions, LLC.</td>
</tr>
<tr>
<td></td>
<td>Judith and Kenneth Simon</td>
</tr>
<tr>
<td></td>
<td>Elisabeth and Alan P. Sklar</td>
</tr>
<tr>
<td>$5,000 - $9,999</td>
<td>Anonymous Donor</td>
</tr>
<tr>
<td></td>
<td>Midge and Greg Bertles</td>
</tr>
<tr>
<td>$100,000 - $249,999</td>
<td>Anonymous Donor</td>
</tr>
<tr>
<td></td>
<td>Accredo Health</td>
</tr>
<tr>
<td></td>
<td>Anonymous Donor</td>
</tr>
<tr>
<td></td>
<td>Ruth and Gordon E. Cadwgan, Jr., Ph.D.</td>
</tr>
<tr>
<td></td>
<td>CVS Health</td>
</tr>
<tr>
<td></td>
<td>Diplomat Specialty Infusion Group</td>
</tr>
<tr>
<td></td>
<td>Eversana</td>
</tr>
<tr>
<td></td>
<td>Facebook Payments, Inc.</td>
</tr>
<tr>
<td></td>
<td>John Laude, Jr.</td>
</tr>
<tr>
<td></td>
<td>Suzanne Schuck Miller</td>
</tr>
<tr>
<td></td>
<td>pH Pharma Co., Ltd.</td>
</tr>
<tr>
<td>$25,000 - $99,999</td>
<td>Anonymous Donor</td>
</tr>
<tr>
<td></td>
<td>Robert B. Webster</td>
</tr>
<tr>
<td></td>
<td>Martin R. Zamora, M.D.</td>
</tr>
</tbody>
</table>
$1,000 - $4,999

Alpha Okies
AmazonSmile Foundation
Donna and James Anderson
Anonymous Donors
Iris Arnowitt
Wendy J. and Aziz I. Asphahani
Alan F. Barker, M.D.
Benefit for Bob Smith
Julie L. Berry
Charles Bissell
Catherine M. and Michael J. Bridgeman
Chris A. Bucek
Mary Beth and Paul O. Byrnes
Charities Aid Foundation of America
Jane-Ellen and Joseph Collins
Creating Healthier Communities
Gwen Cummings
Jeanine M. D’Armiento, M.D., Ph.D.
Jane Davidson
Tami L. Davis
Mark B. Delvaux
Kathleen A. Dodson
James F. Donohue, M.D.
Sally D. and John H. Dorf
William Dye
Enterprise Holdings Foundation
Experience Kissimmee
Susan W. and Donald C. Ferro
Ian F. Fidler
Louis G. Fox
FrontStream Workplace Platform
Jena and Ben Frye
Joan and Oliver Garry
Michelle L. Geris
Karolyn and Stephen Geyen
Martha W. and Roy Girolami
Jean M. and Michael B. Griffith
Miekeleen D. Hart
Haymarket Media, Inc.
Craig P. Hersh, M.D.
Marion T. and Larry L. Hoffman
Bridgette Holbrook

Dave Holtwick
Nancy J. Hughes
Jean and Edd Hyde
Barbara Iglesias
Jeffrey R. Infante
Peg and Peter Iverson
M.C. Jackson, Sr. Family Foundation
Brandy O. and David H. Jesperson
Johnson & Johnson Matching Gifts Program
Deborah H. and Richard C. Keiser
Derek Koecher
Jeffrey C. Kruzel
Betty J. and Alan E. Liberty
Samantha C. Lindsay, M.D.
Catharine MacDonald
Karen and David Maidment
Sandra and Paul Maidment
Jean M. McCathern
Candyce J. and Timothy J. McDonough
Tammy McGuinness
Medical Research Charities
Melissa and Gregory J. Miller
Diane Mohr
Kathleen and John Mylius
Network for Good
Miriam O’Day and Rudy Kusnadi
Michael O’Mara
Oxygen One, Inc.
Palladium Equity Partners
Cherie Patel
Wendy Becker Payton
Ronald H. Pierce
PIP IV, LLC
Shelley J. Pollock
Barbara Poresky
David A. Pusey
Holly and Donovan Quill
Margaret L. Quill
Raising Hope for Others
Tui and Joseph M. “Joe” Reidy
Linda Cromley Renwick
Dorothea “Dot” and Robert A. “Sandy” Sandhaus, M.D., Ph.D.
Joy C. and William J. Schaefer, Jr.
HONOR GALLERY

Sheryl Schey  
John H. Schoolfield  
Anne and Gordon Scott  
Chase Scott  
Martin E. Segal, JD  
Anita and Keith Sellers  
Rebecca E. Snider, M.D.  
Shannon and Adam J. Sonnhalter  
Kimberly L. and Tod A. Stimpson  
Suggs Family Foundation  
Estelle Tenant  
The B.T. Rocca, Jr. Fund  
The Meatlocker  
The Southcott Agency, Inc.  
Trillium Technical  
Ralph Verni  
John R. Wales  
Barbara S. Walker  
Kay and Robert Walter  
Doris and Adam Wanner, M.D.  
Andrew A. Wilson, M.D.  
Judith E. Wilson  
Claudia and D.C. Young  
Your Cause, LLC

Clarissa and Ronald G. Davidson  
Jessica L. Davis  
Kara DesRoche  
Linda and Paul Dougherty  
Kimberly S. and Derek Dozer  
Patricia C. Figgatt  
Mary J. Flury  
Karen and Ron Fraser  
Cristina Friedman  
Laurel C. and Charles W. “Tim” Frost  
Barbara A. Glenn  
Deborah and Daniel F. Grimm  
Elizabeth A. and George B. Hainsworth  
Keith W. Harris, ll  
Linda L. and Edward Hazelbeck  
Cathey F. Henderson  
Angela M. and Eric D. Hoglund  
Bonnie L. and David E. Hoglund  
Thomas R. Holland  
Horae Gene Therapy Center  
David Hosier  
Stephen Hovey  
IBM Employee Services Center  
Patricia A. and Donald E. Janke  
Sarah M. and Richard P. Johnson  
Dara Jolly  
Jennifer M. and Randy P. Jopp  
JPMorgan Charitable Giving Program  
JRT Family Fund – Elizabeth B. Taylor  
Patricia M. Keegan  
Nishla Keiser  
Amy and James Knox  
Camille N. and Darrell N. Kotton, M.D.  
Margot and Jamas W. LaFreniere  
Legacy Ale Works  
Norma I. Leising  
Richard Lesher  
Siobhan C. and Ryan Lestina  
Robert Lieber  
Lighthouse Computer Services, Inc.  
Kathy B. Liu  
Deborah Locke  
Megan L. Lyle  
Michael Maritch  
Patricia A. and Joseph E. Masterson

$500 - $999

Karen S. and John M. Ahearn  
Anonymous Donors  
Arkansas Orthopaedic Center  
Michael E. Bagwell  
Jennifer and Robert Bendetti  
Thomas H. Binnall  
Misty and Greg P. Blessley  
Pamela K. Boetger  
Breathless Wines  
Heidi and Jon Breyer  
Lynda B. Broad  
Mary Buonanno  
William D. Byrne, Jr.  
Michael Cebron  
CMIT Solutions of Cambridge  
William E. Collins  
Lyn-Ann and Robert V. Coombes  
William J. Coyne

Honor Gallery

Gerald McAlevey
Mark McKee
Corinne A. and Donald H. Mitchell
M.S. Walker, Inc.
Christian Mueller, Ph.D.
Julie Murray
Kathy E. and Bruce T. Ogg
Barbara K. Oman
Sharon W. and Barnet Phillips
John R. Ponton, Jr.
Janet L. and Harry Pottinger
Kenneth L. Price
Jean L. Puleo
David S. Pumpelly
Bradley J. Rager
Frances J. Reese
Christopher Rigg
Addison Rubenstein
Saint Mary’s Regional Medical Center
Cynthia Sasso and Daniel Geffken
Paul W. Schaller
Karen R. and John W. Sechrist
Gary J. Seitz
Renie M. Shoberg
Daniel W. Smith
Michael W. Southcott
Spyglass MTG, LLC
Jennifer L. Stack
Terry and James K. Stoller, M.D., M.S.(Org. Dev.)
Pamela and Charlie Strange, M.D.
Strickly Alphas Support Group
Timothy D. Stump
Swan’s Sport Shop
The Cobb Family Foundation
The Lore Kann Foundation
The Ultimate Software Group, Inc.
The William L. Richter Family Foundation
Patricia L. and Kenneth J. Thime
Lisa and Brad Thompson
JP Thornton
Daniel E. Tichon
Jean W. Uptmor
Verisk Analytics

Debbie Waldrop, R.N. M.S.N.
Scott Walls
Megan L. Watkins
Mary E. and Mark D. Wewers, M.D.
Western Mass Environmental, LLC - Dawn Murphy
Memory L. Whitlock
John P. Wilson
Jessica M. and Anthony D. Wisby
Marlene and Thomas B. Witt
Judith A. and James E. Workman
Julie W. Wright
Bradley T. Youngblood

Denotes Deceased
The Alpha-1 Foundation received donations in memory of the following individuals between July 1, 2019 and June 30, 2020.

<table>
<thead>
<tr>
<th>Helen C. Ahearn</th>
<th>Pilar Cabiya</th>
<th>Janet K. Dugmamn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin J. Ahearn</td>
<td>Amelia Cabiya-Martinez</td>
<td>Renee M. Dinnean</td>
</tr>
<tr>
<td>Ann M. Alciatore</td>
<td>Gordon E. Cadwgan, Sr.</td>
<td>Patricia Dix</td>
</tr>
<tr>
<td>Rick Aldrich</td>
<td>Robert C. Campbell</td>
<td>Colleen Dobbs</td>
</tr>
<tr>
<td>Judith L. Anderson</td>
<td>William A. Carey, Ill</td>
<td>Reginald Dorff</td>
</tr>
<tr>
<td>Alpha Angels</td>
<td>Jenni L. Carlock</td>
<td>Randy Ervin Dossat</td>
</tr>
<tr>
<td>Lars A. Anderson</td>
<td>Carolyn J. Carter</td>
<td>Robert J. “Bob” Doughty</td>
</tr>
<tr>
<td>Teresa A. Arominski</td>
<td>Phyllis M. Carter</td>
<td>Thomas John Downie</td>
</tr>
<tr>
<td>Fred Ashmore</td>
<td>Nina Castaneda</td>
<td>Laureen Dunton</td>
</tr>
<tr>
<td>Danny L. Atkins</td>
<td>Sharon Ceroll</td>
<td>Craig A. Dyer</td>
</tr>
<tr>
<td>Arllynn Baber</td>
<td>Gary “Chris” Christensen</td>
<td>Lorraine and LeRoy Ehler</td>
</tr>
<tr>
<td>Berhard “Bernie” Bach</td>
<td>Niels Christensen</td>
<td>John M. “Buddy” Elliott</td>
</tr>
<tr>
<td>Kenneth A. “Kenny” Bakaitis</td>
<td>Charles H. “Chip” Christman</td>
<td>Mary Etter</td>
</tr>
<tr>
<td>Judith “Julie” Crowell Bakula</td>
<td>Charles Christy</td>
<td>Kristin M. Evans</td>
</tr>
<tr>
<td>Magnus Ball</td>
<td>Daniel J. Clark</td>
<td>Sarah E. “Sally” Everett, Esq.</td>
</tr>
<tr>
<td>Betty L. Barnes</td>
<td>Robert D. “Bob” Clark</td>
<td>Donald Fairey</td>
</tr>
<tr>
<td>Paul Barton</td>
<td>Tommy Clayburg</td>
<td>Ralph Farrar</td>
</tr>
<tr>
<td>Kathleen L. Bauernfeind</td>
<td>Allen W. Clowe</td>
<td>Martha J. Faust</td>
</tr>
<tr>
<td>Karen A. Beisang</td>
<td>Lowell E. Cobb, Jr.</td>
<td>Robert Fealy</td>
</tr>
<tr>
<td>William M. Bell</td>
<td>Nancy J. Coleman</td>
<td>Curtis Fendley</td>
</tr>
<tr>
<td>Colin Bender</td>
<td>James P. Cooke</td>
<td>Catherine M. “Cat” Fenner</td>
</tr>
<tr>
<td>David R. Bennett</td>
<td>Robert James Cooke</td>
<td>Nancy Ferguson</td>
</tr>
<tr>
<td>Gladys E. Benson</td>
<td>Stephen E. Cooper</td>
<td>Ron Fields</td>
</tr>
<tr>
<td>Melissa J. Beverly</td>
<td>Jill M. Cornish</td>
<td>Dennis “Denny” Fisher</td>
</tr>
<tr>
<td>Susan K. Binnall</td>
<td>Dennis Cosgrave</td>
<td>Emma Lou M. Fleming</td>
</tr>
<tr>
<td>Bruce “Jack” Bissell</td>
<td>Joe Cosgrave</td>
<td>David Frang</td>
</tr>
<tr>
<td>Ann Clement Black</td>
<td>Eugene L. Cottingham</td>
<td>Ron Fraser</td>
</tr>
<tr>
<td>Karen E. Blunt</td>
<td>Robert Covington</td>
<td>William Fraser</td>
</tr>
<tr>
<td>Richard A. “Rick” Bohn</td>
<td>Timothy D. Craig</td>
<td>Seymour Freedman, M.D.</td>
</tr>
<tr>
<td>James L. “Jim” Boling</td>
<td>Darold Croghan</td>
<td>Philip “Phil” Freeman</td>
</tr>
<tr>
<td>Kenneth Bourgeois</td>
<td>Yerdon Croghan</td>
<td>Roger Fruchey</td>
</tr>
<tr>
<td>Janice G. Bowes</td>
<td>Noah D. Crouch</td>
<td>Karl F. Fuchs</td>
</tr>
<tr>
<td>Edward H. “Ed” Brailey</td>
<td>Evangeline J. Curtis</td>
<td>Sam Fulkerson</td>
</tr>
<tr>
<td>Glen E. Braxton</td>
<td>George D. Dailey, Jr.</td>
<td>Cheryl Galttana</td>
</tr>
<tr>
<td>Roger R. Bray</td>
<td>Norah-Creina “Nickey” Dalzell</td>
<td>Richard K. Camlin</td>
</tr>
<tr>
<td>Alice K. Brazil</td>
<td>Joseph Danley</td>
<td>Theresa M. Gangl</td>
</tr>
<tr>
<td>James “Jim” Brenna</td>
<td>Robert “Bob” Daughtridge</td>
<td>Ray Gastgeb</td>
</tr>
<tr>
<td>Gayle Baine Brezack</td>
<td>Charles L. Davis</td>
<td>David “Wayne” Gates</td>
</tr>
<tr>
<td>Wendy K. Brock</td>
<td>Donald E. Davis, Sr.</td>
<td>Linda M. Gelineau</td>
</tr>
<tr>
<td>Cecil G. “Brock” Brockinton</td>
<td>Eunice G. Davis</td>
<td>Eric Scott Gilbertson</td>
</tr>
<tr>
<td>Alfred H. Brune</td>
<td>Steve Dawson</td>
<td>Warren F. Gilbertson</td>
</tr>
<tr>
<td>Eddie Bryant</td>
<td>Dr. Frederick J. de Serres</td>
<td>Cindy Jo Gill</td>
</tr>
<tr>
<td>Marlene W. Buchanan</td>
<td>Elaine M. Decker</td>
<td>Sharon K. Ginther</td>
</tr>
<tr>
<td>Frances “Sissie” Bueker</td>
<td>Frank Deford</td>
<td>Emma Lou Glenn</td>
</tr>
<tr>
<td>Richard A. “Dick” Bueker</td>
<td>Michael E. DeWald</td>
<td>James “Jim” Charles Goering</td>
</tr>
<tr>
<td>Kenneth F. Busby</td>
<td>Librada Dieguez</td>
<td>Minnie Goodlett</td>
</tr>
</tbody>
</table>
IN MEMORY OF

Frank Granfors  
Larry R. Gray  
Claudia A. Green  
Roger S. Greene, Sr.  
Jean M. Griffith  
Arthur M. Gunter  
Richard “Dick” Guptill  
Larry J. Haan  
Lucas C. Haberstich  
John W. Haggerty  
Mozelle W. Halton  
Steve Alan Handley  
John D. Hanshaw  
JoAnn R. Harkins  
Randall W. Harrington  
Sondra “Ruth” Harrity  
Roy “Randy” Harwell  
Dorothy “Dottie” Hayes  
Thomas C. Hazen  
Nancy Hearte  
Gregory Heath  
John Heidema  
Daniel “Dan” Henderson  
Andrea “Andi” Henry  
Lloyd D. Herlocker  
Pamela Herman  
Julia Hernandez  
Robert H. Hessler  
Daniel W. “Dan” Hicks  
Rebecca Hicks  
Terrance “Terry” Highland  
Richard A. Higby  
Shaylynne S. Hill  
Charles R. Hillegass  
James “Jim” Hixon  
Christina Anna Hoff  
Timothy “Tim” Holdeman  
Rebecca “Becky” Holland  
Dorothy J. Hollern  
Dianna L. Holt  
Anna M. Honnick  
Rhonda Moore Hook  
Jeffrey Scott Horsak  
Richard W. Horsak  
Toni and Keny Hoskins  
William R. Hovis  
William L. “Lou” Hudson, Jr.  
Mark G. Huffaker  
Gregory J. Hules  
Catherine L. Illian  
Jason Imes  
Paige J. Ingrum  
Bettina B. Irvine  
Charles A. Joffrion  
David W. “Dave” Johnson  
Donald Johnston  
Victoria T. “Vicki” Joseph  
David O. Joyce  
Oliver James Joyce  
Alan Kaplan  
Karalee J. Karp  
Russell Kaylor  
Jane MacLeod Keenan  
Rita R. Keir  
Margaret “Peggy” Keith  
Susan H. Kelbaugh  
Catherine M. Kelley  
Arno D. Kester  
Kenneth F. Kiernan  
Brenda Kilner  
David R. Kinnius  
William S. Kirk  
Michael R. “Mike” Kirshman  
Patrick P. Kivland  
Helen Kline  
Helen L. Koenig  
Charles J. Kruger  
John E. Kushner  
Jane Lambert  
Wanda S. Lambert  
Jerome L. “Jerry” Lange  
Deborah A. Lashway  
Robert Lee  
Carla L. Leeder  
Janet Kay Lehmann  
Gregory C. Leigh  
Roberta A. Leslie  
Margaret M. Lewis  
Sandra Lewis  
Alexandra J. “Sandy” Lindsey  
Co-Founder  
Lynda Clare Lindsey  
Nicholas B. Linnenberger  
Kevin W. Little  
Michael G. Locke  
Wanda Logsdon  
Lorna Lomack  
Maria E. Loss  
Lynn M. Lothian  
Ricky Dale Lough  
Mary C. “Candy” Lukenbill  
Robert “Randy” Lyon  
Daniel B. MacArthur  
Stephen Machol  
Patricia E. MacInnes  
Dr. Sharon A. MacLaren  
Robert C. Maffit  
Edward W. Marble, Jr.  
Lynette Marcum  
Gayle Marriott  
Judi R. Matich  
Gracie Mattocks  
Don McAmis  
Alyce Mae (Carlson) Mc Ardle  
Brooke McCarter, Jr.  
William “Billy” McClellan  
Raymond F. McCraren  
James M. McGrane  
Ames McKinsey  
Lawrence P. McNamara  
William McNamara  
Bonny Mears  
Nina S. Meek  
Francis N. Meister  
Joanne M. Mellady  
Robert R. Mercer  
Nancy Merchant  
Jennifer Meredith  
Edward “Ed” Mikell  
Richard K. Mill  
Kimm L. Miller  
Tim Miller  
Leslie F. Millick  
George Mitchell  
Michele D. Mitchell  
Dolline Mixter  
Roger Moline  
R. Bruce Moody, M.D.
IN MEMORY OF

Celeste B. Morris
Joan W. Morse
Brian Moul
Jerry W. Mullen
William Mulqueen
Barbara A. Mulstay
John A. “Jack” Murphy
Shirley Murphey
Thomas J. Myers
Keith Nash
Arthur E. Nealy, Jr.
Dean Nettleton
Patricia E. Dunn Nevers
Carol D. Noggle
Roxanna Nowak
Peter J. O’Hara
Carole O’Mara
Barbara J. Orth
Patti J. Osgar
Oliver H. “Buddy” Otto, Jr.
Bonnie Sue Pace
Jean M. Palaima
Sally Parks
Julianna Patterson
William C. Payne
David M. Perreault
Eric J. Peterson
Calvin T. “Cal” Piearcy
Ronald E. “Ron” Piearcy
Richard Alan Pine
James M. “Jim” Polk
Dennis W. Pollock
Charles Poore
Sandy Peggy Porter
Cynthia M. Potter
David M. Powley
Tammy D. Presley
Leonard R. Pugh
Theodore D. “Ted” Purvis, III
Barbara J. Pusey
The Quill Family
James A. “Jim” Quill
Michael Ratner
Adah R. Reaume
Diann M. Recklein
Robert Rees
Cecil Ray Redmill
William F. Reese
Frank W. Ricker
Marilyn “Lyn” Roberts
Shea Robertson
Lewelyn Rohleder
Mary Beth Roof
Jackson N. Root
Carolyn J. Rose
Judy K. Rose
Mike Rosella
Jodi G. Roth
Edward Roxberry
Jeanne E. Ruff
Fern Croghan Russell
Robert C. Ryan
Carolyn H. Samonds
John Owen Sams
Ivan C. Sauber
Robert Joseph Savard
Kathleen M. Schaefer
Marguerite Adams Schantz
William J. “Bill” Scheuerman
Lawrence Schmidt
Wayne B. Schneck
Sarah Elaine Schonhoff
Nancy Jean Schrum
Edward A. Schuck
Judy Schuck
Allen Schwark
Jim Schwarz
David P. Sechrist
Donald Seffinger
Susan L. Seitz
Joseph W. Seitzer
Aldona J. “Mimi” Sekarski
Wayne A. Simoneau
Mike Skivington
Bob Smith
Lorna Smith
Norma Smith
Richard S. Smith
Vicky Smith
Wilhelm F. Smith
Gordon L. Snider, M.D.
Charles B. Sniffin, Jr.
Davis Snyder
Donna Sommatino
Donald B. Sperling
Jane Bond Sperling
Sammye J. Stacy
Cynthia C. Stamp
Richard G. Stanley
Susan Gerrard Stanley,
Co-Founder
Mary Ann Stanton
John D. Starling
Tyler F. Stearns
Andrew C. “Andy” Steele
Sue Steinmetz
Julia E. Stevens
LaVonne “Scottie” Stewart
Diane S. Stowers
Gus C. Straub
Marta C. Strock
Randall “Randy” Strock
Elizabeth M. Sullivan
Ellen L. Sullivan
Kimberly T. Sullivan
Kathryn “Kay” Kinsel Swift
Edward W. Sylvia
Richard L. Teunissen
Richard D. Tews
James W. Thayer, III
Peter M. Thomson
Donald L. Toland
Jane A. Totten
Kathleen Tracey
Gerald “Jerry” Treichel
Kevin M. Treu
James “Jim” A. Trimble
Steven Trost
Lon E. Tryggestad
Roslyn Upoff
Cathy Urish
Ken Vickers
Barbara Visser
Ed Von Kattengell
Carlyle W. “Hoot” Wacker
Thomas K. Wall
Helen Chase Walsh
Jack “Coach” Walsh
IN MEMORY OF

John W. Walsh, Co-Founder
Joan O. Warren
Howard Werdehoff
Clifford E. “Cliff” Wheeler
Cheryl K. Whitaker
Norma L. Whitaker
Ralph “Steve” Whitlock
Douglas Wiles
John O. Will
Elijah Williams
Patricia G. Williams
Edward T. Wilson
Richard L. Wilson
Brady L. Woessner
Gary Wolf
Mary Ann Workman
Jackie L. Wriston
Willogene Wriston
Louise A. Wunderly
Terry L. Young
Alyce M. Yout
Emma R. Yriberry
IN HONOR OF

Colleen and Doug Peters  Erin M. Wisch
Paulette Pipher  Casey Wolff
Patrick Pollifrone  Mandy Wright
Timothy Powell  Claudia and DC Young
Albert W. “Ab” Rees  Alexander Zelk
Joseph M. “Joe” Reidy  Joseph H. Zuraw
Sam Reynolds
Clarissa D. Riely
Ethan Roehrich
Robert “Bob” Rowe
Velvet K. Rumfield
  Dorothea “Dot” Sandhaus
  Robert A. “Sandy” Sandhaus, M.D., Ph.D.
Joy C. Schaefer
Joyce K. Schools
Teri Schwartz
Norah Schweitzer
  Alexandria Sonnhalter
  Jackson Sonnhalter
William T. Spilker
Harrison Clay Stephens
Charlie Strange, M.D.
Barry V. Swing
Lawrence Tandol
Patty L. Tew
Dee D. Towle
Justin M. Vincent
Kaitlin A. Vincent
Emuna and Yehuda Walker
Chase W. Walsh
Diane L. Walsh
Juba Walsh
Kailey W. Walsh
Linda J. Walsh
Pamela and Fred C. Walsh
Dr. Adam Wanner
Virginia “Ginger” Watkins
Deborah Webb-Howells
Nancy D. Wheeler
Pamela D. White
John C. “Jay” Whitmore, Jr.
Robert N. Williams
Tim Williams
Graham Willock

Denotes Deceased
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

The Alpha-1 Foundation has invested $81 million to support Alpha-1 research and programs at 116 institutions in North America, Europe, the Middle East, and Australia.

www.alpha1.org
1 (877) 2 CURE A1 | 1 (877) 228-7321